Martin Seidel, NIBR’s global head of strategic alliances, gets things underway.

From left: Peter Barrett, Tom Hughes, and Bruce Booth share a laugh recounting Hughes’ initial disinterest in running Zafgen.

Never forget your notepad at one of these events, you just might learn something.

Robert Gould talks being pitched about Epizyme: “it was a fundamental area of biology, a fundamental opportunity, particularly in the field of cancer.” He was named the company’s CEO in 2010.

Not a seat in the house as Bay City Capital’s Carl Goldfischer talks the pros and cons of pushing for an IPO or a sale.

Profound thoughts, indeed.

Though sporting the best shoes in the house, Kevin Starr (r.) gives more than just fashion lessons. Sage CEO Jeff Jonas looks on.

Jonas had the crowd rolling recounting his first pitch from Sage, and the “farkakt indications,” it first intended to pursue.

Let the post-event mingling begin.

Only the healthiest grub for our attendees. This is a healthcare event after all.

Why would Epizyme go public? I mean come on, it’s way easier to sell.

Is this a drone strike? No, our photographer will find you from any angle.

The business card exchange; an event tradition.

Connections are made over drinks and veggies.

It’s only a matter of time before someone spots our camera man.

Whatever you do, DON’T try and go public without testing the waters first.

Special thanks to all of our attendees for making this event a success. We’ll see you again for the Healthcare Summit in November.